{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:06:41Z","timestamp":1789913201044,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40265-019-01091-3","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T08:08:34Z","timestamp":1553069314000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Tofacitinib: A Review in Psoriatic Arthritis"],"prefix":"10.1007","volume":"79","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"issue":"Suppl 2","key":"1091_CR1","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"1091_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatol (Oxf). 2003;42(12):1460\u20138.","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"1091_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2012","unstructured":"Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51(3):571\u20136.","journal-title":"Rheumatology (Oxford)."},{"issue":"21","key":"1091_CR4","first-page":"2095","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095\u20136.","journal-title":"N Engl J Med."},{"issue":"10","key":"1091_CR5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"A-M Orbai","year":"2017","unstructured":"Orbai A-M, de Wit M, Mease PJ, et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J Rheumatol. 2017;44(10):1522\u20138.","journal-title":"J Rheumatol."},{"issue":"5","key":"1091_CR6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"1091_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K Vlam de","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627\u201334.","journal-title":"Acta Derm Venereol."},{"issue":"1","key":"1091_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387.","journal-title":"Immunol Rev."},{"key":"1091_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key070","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatol (Oxf). 2018. https:\/\/doi.org\/10.1093\/rheumatology\/key070 .","journal-title":"Rheumatol (Oxf)."},{"issue":"2","key":"1091_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA. Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231\u201341.","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"1091_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s10067-015-3002-2","volume":"34","author":"U Fiocco","year":"2015","unstructured":"Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34(9):1571\u201380.","journal-title":"Clin Rheumatol."},{"issue":"10","key":"1091_CR12","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","volume":"76","author":"SK Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76(10):e36.","journal-title":"Ann Rheum Dis."},{"key":"1091_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3899\/jrheum.150636","volume":"93","author":"U Fiocco","year":"2015","unstructured":"Fiocco U, Martini V, Accordi B, et al. Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints. J Rheumatol Suppl. 2015;93:48\u201352.","journal-title":"J Rheumatol Suppl."},{"key":"1091_CR14","unstructured":"Pfizer. Xeljanz: EU summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/. Accessed 4 Mar 2019."},{"key":"1091_CR15","unstructured":"Pfizer. XELJANZ\u00ae\/XR (tofacitinib): US prescribing information. 2016. https:\/\/www.accessdata.fda.gov\/. Accessed 4 Mar 2019."},{"issue":"8","key":"1091_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","volume":"73","author":"LJ Scott","year":"2013","unstructured":"Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs. 2013;73(8):857\u201374.","journal-title":"Drugs."},{"issue":"18","key":"1091_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77(18):1987\u20132001.","journal-title":"Drugs."},{"issue":"16","key":"1091_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med."},{"issue":"16","key":"1091_CR19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336.","journal-title":"N Engl J Med."},{"issue":"11","key":"1091_CR20","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461\u20135.","journal-title":"J Rheumatol."},{"key":"1091_CR21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180971","author":"D Heijde van der","year":"2019","unstructured":"van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis patients treated with tofacitinib or adalimumab. J Rheumatol. 2019. https:\/\/doi.org\/10.3899\/jrheum.180971 .","journal-title":"J Rheumatol."},{"issue":"1","key":"1091_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","volume":"20","author":"P Helliwell","year":"2018","unstructured":"Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"1091_CR23","doi-asserted-by":"publisher","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden: a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.","journal-title":"RMD Open."},{"key":"1091_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000808","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019. https:\/\/doi.org\/10.1136\/rmdopen-2018-000808 .","journal-title":"RMD Open."},{"issue":"2","key":"1091_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","volume":"5","author":"P Nash","year":"2018","unstructured":"Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5(2):567\u201382.","journal-title":"Rheumatol Ther."},{"issue":"Suppl 2","key":"1091_CR26","first-page":"1010","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of OPAL Balance, an open-label, long-term extension study [abstract no. SAT0293]. Ann Rheum Dis. 2018;77(Suppl 2):1010\u20131.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"1091_CR27","first-page":"1023","volume":"77","author":"C Ritchlin","year":"2018","unstructured":"Ritchlin C, Giles J, Ogdie A, et al. Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies [abstract no. SAT0317]. Ann Rheum Dis. 2018;77(Suppl 2):1023.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"1091_CR28","first-page":"938","volume":"76","author":"G Burmester","year":"2017","unstructured":"Burmester G, FitzGerald O, Winthrop K, et al. Integrated safety summary of tofacitinib in psoriatic arthritis clinical studies [abstract no. SAT0439]. Ann Rheum Dis. 2017;76(Suppl 2):938.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"1091_CR29","first-page":"1030","volume":"77","author":"G Burmester","year":"2018","unstructured":"Burmester G, Rigby WFC, Choy E, et al. Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis [abstract no. SAT0330]. Ann Rheum Dis. 2018;77(Suppl 2):1030.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"1091_CR30","first-page":"368","volume":"77","author":"DD Gladman","year":"2018","unstructured":"Gladman DD, Charles-Schoeman C, McInnes IB, et al. An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies [abstract no. THU0299]. Ann Rheum Dis. 2018;77(Suppl 2):368.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"1091_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1091_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs."},{"issue":"8","key":"1091_CR33","first-page":"408","volume":"11","author":"Y Xu","year":"2018","unstructured":"Xu Y, Sudharshan L, Hsu MA, et al. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. Am Health Drug Benefits. 2018;11(8):408\u201317.","journal-title":"Am Health Drug Benefits"},{"issue":"Suppl 2","key":"1091_CR34","first-page":"368","volume":"77","author":"DD Gladman","year":"2018","unstructured":"Gladman DD, Orbai AM, Gomez-Reino J, et al. Network meta-analysis of tofacitinib vs bDMARDs or apremilast for the treatment of TNF inhibitor-na\u00efve patients with psoriatic arthritis [abstract no. THU0300]. Ann Rheum Dis. 2018;77(Suppl 2):368","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"1091_CR35","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"9999","key":"1091_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet."},{"issue":"Suppl 10","key":"1091_CR37","first-page":"676","volume":"69","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Yun H, Gerald OF, et al. Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data [abstract no. 617]. Arthritis Rheumatol. 2017;69(Suppl 10):676.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"1091_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-016-0602-3","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M, Scott LJ. Secukinumab: a review in psoriatic arthritis. Drugs. 2016;76(11):1135\u201345.","journal-title":"Drugs."},{"issue":"9","key":"1091_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40265-014-0242-4","volume":"74","author":"K McKeage","year":"2014","unstructured":"McKeage K. Ustekinumab: a review of its use in psoriatic arthritis. Drugs. 2014;74(9):1029\u201339.","journal-title":"Drugs."},{"issue":"4","key":"1091_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459\u201372.","journal-title":"Drugs."},{"key":"1091_CR41","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2147\/PPA.S117774","volume":"10","author":"R Alten","year":"2016","unstructured":"Alten R, Kruger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217\u201328.","journal-title":"Patient Prefer Adherence."},{"issue":"2","key":"1091_CR42","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib: an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol."},{"key":"1091_CR43","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): assessment report. 2017. http:\/\/www.ema.europa.eu\/. Accessed 4 Mar 2019."},{"issue":"1","key":"1091_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","volume":"75","author":"W Gao","year":"2016","unstructured":"Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75(1):311\u20135.","journal-title":"Ann Rheum Dis."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01091-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T23:10:39Z","timestamp":1721085039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01091-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01091-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"20 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Paik and Emma Deeks are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}